Emerging roles of intratumor microbiota in cancer: tumorigenesis and management strategies | Journal of Translational Medicine
Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369–79.
Google Scholar
Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164(3):337–40.
Google Scholar
Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.
Google Scholar
O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688–93.
Google Scholar
Schupack DA, et al. The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol. 2022;19(1):7–25.
Google Scholar
Nejman D, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368(6494):973–80.
Google Scholar
Sepich-Poore GD, et al. The microbiome and human cancer. Science. 2021;371(6536):4552.
Google Scholar
Meng YF, et al. Role of the intratumoral microbiome in tumor progression and therapeutics implications. Biochim Biophys Acta Rev Cancer. 2023;1878(6): 189014.
Google Scholar
Biological agents. IARC Monogr Eval Carcinog Risks Hum, 2012. 100(Pt B): p. 1–441.
de Martel C, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–90.
Google Scholar
Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J. 2003;79(938):672–80.
Google Scholar
Turner T, Caspari T. When heat casts a spell on the DNA damage checkpoints. Open Biol. 2014;4(3): 140008.
Google Scholar
Hobohm U. Fever therapy revisited. Br J Cancer. 2005;92(3):421–5.
Google Scholar
Hoption Cann SA, et al. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses. 2002;58(2):115–9.
Google Scholar
Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley’s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl. 1953;276:1–103.
Google Scholar
Bassi P. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol. 2002;11(1–2):77–83.
Google Scholar
Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008;179(1):53–6.
Google Scholar
Budynek P, et al. Bacteriophages and cancer. Arch Microbiol. 2010;192(5):315–20.
Google Scholar
Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer. 2016;16(12):789–802.
Google Scholar
Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15(11):e517–26.
Google Scholar
Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1(7335):702–3.
Google Scholar
Khan G, Hashim MJ. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990–2010. Infect Agent Cancer. 2014;9(1):38.
Google Scholar
Shalhout SZ, et al. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160–77.
Google Scholar
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.
Google Scholar
Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136(6):1863–73.
Google Scholar
Narunsky-Haziza L, et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell. 2022;185(20):3789-3806.e17.
Google Scholar
Dohlman AB, et al. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell. 2022;185(20):3807-3822.e12.
Google Scholar
Lu YQ, et al. Broadening oncological boundaries: the intratumoral microbiota. Trends Microbiol. 2024. https://doi.org/10.1016/j.tim.2024.01.007.
Google Scholar
Caporaso JG, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4516–22.
Google Scholar
Quince C, et al. Shotgun metagenomics, from sampling to analysis. Nat Biotechnol. 2017;35(9):833–44.
Google Scholar
Fu A, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell. 2022;185(8):1356-1372.e26.
Google Scholar
Massironi S, et al. Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study. Cells. 2022;11(4):692.
Google Scholar
Phelps CM, et al. Detection of viable commensal bacteria in murine melanoma tumors by culturomics. STAR Protoc. 2023;4(3): 102492.
Google Scholar
Dumont-Leblond N, et al. Non-small cell lung cancer microbiota characterization: prevalence of enteric and potentially pathogenic bacteria in cancer tissues. PLoS ONE. 2021;16(4): e0249832.
Google Scholar
Wong-Rolle A, et al. Spatial meta-transcriptomics reveal associations of intratumor bacteria burden with lung cancer cells showing a distinct oncogenic signature. J Immunother Cancer. 2022;10(7): e004698.
Google Scholar
Zhang M, et al. Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection. Transl Cancer Res. 2022;11(2):426–34.
Google Scholar
Liu NN, et al. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell. 2023;41(11):1927-1944.e9.
Google Scholar
Wang Y, et al. Intra-tumoral microbial community profiling and associated metabolites alterations of TNBC. Front Oncol. 2023;13:1143163.
Google Scholar
Chang J, et al. Potential values of formalin-fixed paraffin-embedded tissues for intratumoral microbiome analysis in breast cancer. Heliyon. 2023;9(6): e16267.
Google Scholar
Huang JH, et al. The intratumoral bacterial metataxonomic signature of hepatocellular carcinoma. Microbiol Spectr. 2022;10(5): e0098322.
Google Scholar
Qu D, et al. Intratumoral microbiome of human primary liver cancer. Hepatol Commun. 2022;6(7):1741–52.
Google Scholar
Chai X, et al. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma. Gut Microbes. 2023;15(1):2156255.
Google Scholar
He Y, et al. Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues. J Transl Med. 2023;21(1):68.
Google Scholar
Qiao K, et al. Intratumor mycoplasma promotes the initiation and progression of hepatocellular carcinoma. Cell Rep. 2023;42(12): 113563.
Google Scholar
Sun L, et al. Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery. Clin Transl Med. 2023;13(7): e1331.
Google Scholar
Liu W, et al. Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis. Gastroenterology. 2021;160(7):2395–408.
Google Scholar
Okuda S, et al. Profiling of host genetic alterations and intra-tumor microbiomes in colorectal cancer. Comput Struct Biotechnol J. 2021;19:3330–8.
Google Scholar
Barot SV, et al. Distinct intratumoral microbiome of young-onset and average-onset colorectal cancer. EBioMedicine. 2024;100: 104980.
Google Scholar
Joo JE, et al. Intratumoral presence of the genotoxic gut bacteria pks(+) E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer. Br J Cancer. 2024. https://doi.org/10.1038/s41416-023-02554-x.
Google Scholar
Peng R, et al. Gastric microbiome alterations are associated with decreased CD8+ tissue-resident memory T cells in the tumor microenvironment of gastric cancer. Cancer Immunol Res. 2022;10(10):1224–40.
Google Scholar
Fu K, et al. Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell. 2024;187(4):882-896.e17.
Google Scholar
Baba Y, et al. Relationship between gut microbiome Fusobacterium nucleatum and LINE-1 methylation level in esophageal cancer. Esophagus. 2023;20(4):704–12.
Google Scholar
Kosumi K, et al. Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer. Br J Cancer. 2023;128(6):1155–65.
Google Scholar
Li Y, et al. Intracellular Fusobacterium nucleatum infection attenuates antitumor immunity in esophageal squamous cell carcinoma. Nat Commun. 2023;14(1):5788.
Google Scholar
Wu H, et al. Intratumoral microbiota composition regulates chemoimmunotherapy response in esophageal squamous cell carcinoma. Cancer Res. 2023. https://doi.org/10.1158/0008-5472.CAN-22-2593.
Google Scholar
Huang Y, et al. Intratumor microbiome analysis identifies positive association between megasphaera and survival of Chinese patients with pancreatic ductal adenocarcinomas. Front Immunol. 2022;13: 785422.
Google Scholar
Tan Q, et al. Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils. Gut Microbes. 2022;14(1):2073785.
Google Scholar
Hayashi M, et al. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis. Cancer Sci. 2023;114(9):3666–78.
Google Scholar
Abe S, et al. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma. J Gastroenterol. 2024. https://doi.org/10.1007/s00535-023-02069-5.
Google Scholar
Neuzillet C, et al. Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients. Sci Rep. 2021;11(1):7870.
Google Scholar
Qiao H, et al. Association of intratumoral microbiota with prognosis in patients with nasopharyngeal carcinoma from 2 hospitals in China. JAMA Oncol. 2022;8(9):1301–9.
Google Scholar
Zeng B, et al. The oral cancer microbiome contains tumor space-specific and clinicopathology-specific bacteria. Front Cell Infect Microbiol. 2022;12: 942328.
Google Scholar
Pratap Singh R, et al. Intratumoral microbiota changes with tumor stage and influences the immune signature of oral squamous cell carcinoma. Microbiol Spectr. 2023;11(4): e0459622.
Google Scholar
Wang J, et al. Uncovering the microbiota in renal cell carcinoma tissue using 16S rRNA gene sequencing. J Cancer Res Clin Oncol. 2021;147(2):481–91.
Google Scholar
Hawkins GM, et al. Differences in the microbial profiles of early stage endometrial cancers between black and white women. Gynecol Oncol. 2022;165(2):248–56.
Google Scholar
Huang Q, et al. Endogenous propionibacterium acnes promotes ovarian cancer progression via regulating hedgehog signalling pathway. Cancers (Basel). 2022;14(21):5178.
Google Scholar
Yuan L, et al. Tumor microbiome diversity influences papillary thyroid cancer invasion. Commun Biol. 2022;5(1):864.
Google Scholar
Cantini G, et al. Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane. Endocr Relat Cancer. 2023. https://doi.org/10.1530/ERC-23-0094.
Google Scholar
Perry LM, et al. Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis. J Immunother Cancer. 2023;11(1): e004285.
Google Scholar
Rustetska N, et al. The intratumour microbiota and neutrophilic inflammation in squamous cell vulvar carcinoma microenvironment. J Transl Med. 2023;21(1):285.
Google Scholar
Ye L, et al. Evidence for an intra-tumoral microbiome in pituitary neuroendocrine tumors with different clinical phenotypes. J Neurooncol. 2023;163(1):133–42.
Google Scholar
Swanton C, et al. Embracing cancer complexity: hallmarks of systemic disease. Cell. 2024;187(7):1589–616.
Google Scholar
Kong C, et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Gut. 2022. https://doi.org/10.1136/gutjnl-2022-327156.
Google Scholar
Zhu H, et al. Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15. Nat Commun. 2024;15(1):1688.
Google Scholar
Park HE, et al. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Arch. 2017;471(3):329–36.
Google Scholar
Zepeda-Rivera M, et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature. 2024;628(8007):424–32.
Google Scholar
Liao Y, et al. Microbes translocation from oral cavity to nasopharyngeal carcinoma in patients. Nat Commun. 2024;15(1):1645.
Google Scholar
Yang L, et al. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther. 2023;8(1):35.
Google Scholar
Cao Y, et al. Intratumoural microbiota: a new frontier in cancer development and therapy. Signal Transduct Target Ther. 2024;9(1):15.
Google Scholar
Yamamoto S, et al. Heterogeneous distribution of Fusobacterium nucleatum in the progression of colorectal cancer. J Gastroenterol Hepatol. 2021;36(7):1869–76.
Google Scholar
Bertocchi A, et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell. 2021;39(5):708-724.e11.
Google Scholar
Zhu Z, et al. Microbiome and spatially resolved metabolomics analysis reveal the anticancer role of gut Akkermansia muciniphila by crosstalk with intratumoral microbiota and reprogramming tumoral metabolism in mice. Gut Microbes. 2023;15(1):2166700.
Google Scholar
Choi Y, et al. Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity. Sci Immunol. 2023;8(81):eabo2003.
Google Scholar
Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628–38.
Google Scholar
Ciernikova S, et al. Tumor microbiome—an integral part of the tumor microenvironment. Front Oncol. 2022;12:1063100.
Google Scholar
Li Y, et al. Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell Rep Med. 2024;5:101397.
Google Scholar
Cao Y, et al. Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites. Science. 2022;378(6618):eabm3233.
Google Scholar
Pleguezuelos-Manzano C, et al. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli. Nature. 2020;580(7802):269–73.
Google Scholar
Miyakawa Y, et al. Gut Bacteria-derived membrane vesicles induce colonic dysplasia by inducing DNA damage in colon epithelial cells. Cell Mol Gastroenterol Hepatol. 2024;17(5):745–67.
Google Scholar
He Z, et al. Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. Gut. 2019;68(2):289–300.
Google Scholar
Srivatsav AT, Kapoor S. The emerging world of membrane vesicles: functional relevance, theranostic avenues and tools for investigating membrane function. Front Mol Biosci. 2021;8: 640355.
Google Scholar
Ma Y, et al. Intratumor microbiome-derived butyrate promotes lung cancer metastasis. Cell Rep Med. 2024;5(4): 101488.
Google Scholar
Sun X, Zhu MJ. Butyrate inhibits indices of colorectal carcinogenesis via enhancing α-ketoglutarate-dependent DNA demethylation of mismatch repair genes. Mol Nutr Food Res. 2018;62(10): e1700932.
Google Scholar
Mowat C, et al. Short chain fatty acids prime colorectal cancer cells to activate antitumor immunity. Front Immunol. 2023;14:1190810.
Google Scholar
Mirzaei R, et al. Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother. 2021;139: 111619.
Google Scholar
Pushalkar S, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8(4):403–16.
Google Scholar
Kalaora S, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021;592(7852):138–43.
Google Scholar
Battaglia TW, et al. A pan-cancer analysis of the microbiome in metastatic cancer. Cell. 2024;187(9):2324-2335.e19.
Google Scholar
Triner D, et al. Neutrophils restrict tumor-associated microbiota to reduce growth and invasion of colon tumors in mice. Gastroenterology. 2019;156(5):1467–82.
Google Scholar
Chen Z, Huang L. Fusobacterium nucleatum carcinogenesis and drug delivery interventions. Adv Drug Deliv Rev. 2024;209: 115319.
Google Scholar
Wu Y, et al. Fn-Dps, a novel virulence factor of Fusobacterium nucleatum, disrupts erythrocytes and promotes metastasis in colorectal cancer. PLoS Pathog. 2023;19(1): e1011096.
Google Scholar
Nie F, et al. The role of CXCL2-mediated crosstalk between tumor cells and macrophages in Fusobacterium nucleatum-promoted oral squamous cell carcinoma progression. Cell Death Dis. 2024;15(4):277.
Google Scholar
Ren J, et al. P. gingivalis infection upregulates PD-L1 expression on dendritic cells, suppresses CD8+ T-cell responses, and aggravates oral cancer. Cancer Immunol Res. 2023;11(3):290–305.
Google Scholar
Yáñez L, et al. Co-culture of P. gingivalis and F. nucleatum synergistically elevates IL-6 expression via TLR4 signaling in oral keratinocytes. Int J Mol Sci. 2024;25(7):3611.
Google Scholar
Alam A, et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell. 2022;40(2):153-167.e11.
Google Scholar
Brandstadter JD, Yang Y. Natural killer cell responses to viral infection. J Innate Immun. 2011;3(3):274–9.
Google Scholar
Ou S, et al. Fusobacterium nucleatum upregulates MMP7 to promote metastasis-related characteristics of colorectal cancer cell via activating MAPK(JNK)-AP1 axis. J Transl Med. 2023;21(1):704.
Google Scholar
Sueh CY, et al. Fusobacterium nucleatum impairs DNA mismatch repair and stability in patients with squamous cell carcinoma of the head and neck. Cancer. 2022;128(17):3170–84.
Google Scholar
Zhang W, et al. Microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling. Cell Oncol (Dordr). 2024. https://doi.org/10.1007/s13402-024-00920-2.
Google Scholar
Ma W, et al. Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1. Protein Cell. 2024. https://doi.org/10.1093/procel/pwae005.
Google Scholar
Kong C, et al. Fusobacterium nucleatum promotes the development of colorectal cancer by activating a cytochrome P450/epoxyoctadecenoic acid axis via TLR4/Keap1/NRF2 signaling. Cancer Res. 2021;81(17):4485–98.
Google Scholar
Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80–6.
Google Scholar
Lam KC, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021;184(21):5338-5356.e21.
Google Scholar
Shi Y, et al. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 2020;217(5): e20192282.
Google Scholar
Jing W, et al. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer. 2019;7(1):115.
Google Scholar
Fu A, et al. Emerging roles of intratumor microbiota in cancer metastasis. Trends Cell Biol. 2023;33(7):583–93.
Google Scholar
Hilmi M, et al. Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: an ancillary study of the SHIVA clinical trial. Eur J Cancer. 2023;183:152–61.
Google Scholar
Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89.
Google Scholar
Che S, et al. Unveiling the intratumoral microbiota within cancer landscapes. iScience. 2024;27(6): 109893.
Google Scholar
Yang Y, et al. Fusobacterium nucleatum Increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21. Gastroenterology. 2017;152(4):851-866.e24.
Google Scholar
Tang B, et al. MicroRNA-31 induced by Fusobacterium nucleatum infection promotes colorectal cancer tumorigenesis. SiScience. 2023;26(5): 106770.
Google Scholar
Zhang M, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis by excretion of miR-122–5p from cells via exosomes. iScience. 2023;26(9): 107686.
Google Scholar
Guo S, et al. Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16. Gut. 2020. https://doi.org/10.1136/gutjnl-2020-321187.
Google Scholar
Lu X, et al. Long non-coding RNA EVADR induced by Fusobacterium nucleatum infection promotes colorectal cancer metastasis. Cell Rep. 2022;40(3): 111127.
Google Scholar
Xu C, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. 2021;13(1):1980347.
Google Scholar
Zhang S, et al. Fusobacterium nucleatum promotes epithelial-mesenchymal transiton through regulation of the lncRNA MIR4435-2HG/miR-296-5p/Akt2/SNAI1 signaling pathway. Febs j. 2020;287(18):4032–47.
Google Scholar
Hui B, et al. Exosomes secreted by Fusobacterium nucleatum-infected colon cancer cells transmit resistance to oxaliplatin and 5-FU by delivering hsa_circ_0004085. J Nanobiotechnology. 2024;22(1):62.
Google Scholar
Zeng W, Pan J, Ye G. miR-135b aggravates fusobacterium nucleatum-induced cisplatin resistance in colorectal cancer by targeting KLF13. J Microbiol. 2024;62(2):63–73.
Google Scholar
Hong J, et al. F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. Gut. 2021;70(11):2123–37.
Google Scholar
Sun J, et al. F. nucleatum facilitates oral squamous cell carcinoma progression via GLUT1-driven lactate production. EBioMedicine. 2023;88:104444.
Google Scholar
Yamamura K, et al. Intratumoral Fusobacterium nucleatum levels predict therapeutic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Clin Cancer Res. 2019;25(20):6170–9.
Google Scholar
Huang ST, et al. Intratumoral levels and prognostic significance of Fusobacterium nucleatum in cervical carcinoma. Aging (Albany NY). 2020;12(22):23337–50.
Google Scholar
Mima K, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973–80.
Google Scholar
Mouradov D, et al. Oncomicrobial community profiling identifies clinicomolecular and prognostic subtypes of colorectal cancer. Gastroenterology. 2023;165(1):104–20.
Google Scholar
Zhang Y, et al. Pan-cancer analyses reveal the stratification of patient prognosis by viral composition in tumor tissues. Comput Biol Med. 2023;167: 107586.
Google Scholar
Huang X, et al. Metagenomic analysis of intratumoral microbiome linking to response to neoadjuvant chemoradiotherapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2023;117(5):1255–69.
Google Scholar
Colbert LE, et al. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023. https://doi.org/10.1016/j.ccell.2023.09.012.
Google Scholar
Wang N, et al. Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. Gut Microbes. 2024;16(1):2333790.
Google Scholar
Li B, et al. Fusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin/β-catenin/GPX4 axis in colorectal cancer. Free Radic Biol Med. 2024. https://doi.org/10.1016/j.freeradbiomed.2024.04.226.
Google Scholar
LaCourse KD, et al. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. Cell Rep. 2022;41(7): 111625.
Google Scholar
Li G, et al. Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3. EBioMedicine. 2024;102: 105041.
Google Scholar
Dalmasso G, et al. Colibactin-producing Escherichia coli enhance resistance to chemotherapeutic drugs by promoting epithelial to mesenchymal transition and cancer stem cell emergence. Gut Microbes. 2024;16(1):2310215.
Google Scholar
Guillot N, et al. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality. Trends Mol Med. 2023;29(11):897–911.
Google Scholar
Bender MJ, et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. 2023;186(9):1846-1862.e26.
Google Scholar
Dana H, et al. CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021;11(5):1129–47.
Google Scholar
Wang G, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023;31(1):134–53.
Google Scholar
Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
Google Scholar
Shi Z, et al. Emerging roles of the gut microbiota in cancer immunotherapy. Front Immunol. 2023;14:1139821.
Google Scholar
Wang M, et al. Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses. Nat Biotechnol. 2023. https://doi.org/10.1038/s41587-023-01957-8.
Google Scholar
Gao C, et al. Synergistic target of intratumoral microbiome and tumor by metronidazole-fluorouridine nanoparticles. ACS Nano. 2023;17(8):7335–51.
Google Scholar
Caproni E, et al. Anti-tumor efficacy of in situ vaccination using bacterial outer membrane vesicles. Cancers (Basel). 2023;15(13):3328.
Google Scholar
Peng S, et al. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. Cancer Immunol Immunother. 2021;70(4):1049–62.
Google Scholar
Zalatan JG, Petrini L, Geiger R. Engineering bacteria for cancer immunotherapy. Curr Opin Biotechnol. 2024;85: 103061.
Google Scholar
Suh S, et al. Nanoscale bacteria-enabled autonomous drug delivery system (NanoBEADS) enhances intratumoral transport of nanomedicine. Adv Sci (Weinh). 2019;6(3):1801309.
Google Scholar
Gurbatri CR, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020;12(530):eaax0876.
Google Scholar
Savage TM, et al. Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity. Sci Adv. 2023;9(10):eadc9436.
Google Scholar
Luke JJ, et al. Phase I study of SYNB1891, an engineered E. coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res. 2023;29(13):2435–44.
Google Scholar
Zhou S, et al. Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma. J Immunother Cancer. 2024;12(2): e008238.
Google Scholar
Guo L, Ding J, Zhou W. Converting bacteria into autologous tumor vaccine via surface biomineralization of calcium carbonate for enhanced immunotherapy. Acta Pharm Sin B. 2023;13(12):5074–90.
Google Scholar
Zhu J, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun. 2022;13(1):7466.
Google Scholar
Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7(1):117.
Google Scholar
Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373–9.
Google Scholar
Abd-Aziz N, Poh CL. Development of oncolytic viruses for cancer therapy. Transl Res. 2021;237:98–123.
Google Scholar
Wang S, et al. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy. J Immunother Cancer. 2024;12(3):e008431.
Google Scholar
Ban W, et al. Emerging systemic delivery strategies of oncolytic viruses: a key step toward cancer immunotherapy. Nano Res. 2022;15(5):4137–53.
Google Scholar
Lou J, et al. Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes. Biosci Rep. 2021;41(6):BSR20204186.
Google Scholar
Kajiwara Y, et al. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunol Immunother. 2023;72(5):1285–300.
Google Scholar
Chen L, et al. Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma. Mol Ther Oncolytics. 2022;24:522–34.
Google Scholar
Toulmonde M, et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide. Mol Cancer. 2024;23(1):38.
Google Scholar
Panagioti E, et al. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. J Clin Invest. 2021;131(13): e141614.
Google Scholar
Huang L, et al. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer. Cancer Med. 2022;11(23):4575–87.
Google Scholar
Sun K, et al. A phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and in situ virus gene therapy in metastatic triple-negative breast cancer. Clin Cancer Res. 2022;28(20):4392–401.
Google Scholar
Rudin CM, et al. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. J Immunother Cancer. 2023;11(1): e005007.
Google Scholar
Fakih M, et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE). J Immunother Cancer. 2023;11(4):e006561.
Google Scholar
Nassiri F, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. 2023;29(6):1370–8.
Google Scholar
Silk AW, et al. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. Cancer Immunol Immunother. 2023;72(6):1405–15.
Google Scholar
Gui M, et al. Swine pseudorabies virus attenuated vaccine reprograms the kidney cancer tumor microenvironment and synergizes with PD-1 blockade. J Med Virol. 2024;96(4): e29568.
Google Scholar
Park JS, et al. PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma. Cancer Cell Int. 2024;24(1):50.
Google Scholar
Yu H, et al. Combination immunotherapy of oncolytic flu-vectored virus and programmed cell death 1 blockade enhances antitumor activity in hepatocellular carcinoma. Hum Gene Ther. 2024;35(5–6):177–91.
Google Scholar
Curti BD, et al. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. J Immunother Cancer. 2022;10(12): e005224.
Google Scholar
Chesney JA, et al. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J Immunother Cancer. 2023;11(5): e006270.
Google Scholar
Lutzky J, et al. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2023;149(9):6059–66.
Google Scholar
Zuo S, et al. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. J Immunother Cancer. 2021;9(12): e002843.
Google Scholar
Ju F, et al. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. J Immunother Cancer. 2022;10(6): e004762.
Google Scholar
Monge C, et al. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. J Immunother Cancer. 2023;11(2): e005640.
Google Scholar
Rosewell Shaw A, et al. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021;4(1):368.
Google Scholar
Huang J, et al. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother. 2021;70(9):2453–65.
Google Scholar
Wenthe J, et al. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. Cancer Immunol Immunother. 2021;70(10):2851–65.
Google Scholar
Chalise L, et al. Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma. Mol Ther Oncolytics. 2022;26:265–74.
Google Scholar
Evgin L, et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022;14(640):eabn2231.
Google Scholar
Sonzogni O, et al. T-SIGn tumor reengineering therapy and CAR T cells synergize in combination therapy to clear human lung tumor xenografts and lung metastases in NSG mice. Oncoimmunology. 2022;11(1):2029070.
Google Scholar
Zhu G, et al. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma. Cancer Immunol Immunother. 2022;71(10):2433–48.
Google Scholar
Fang L, et al. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma. Pharmacol Res. 2023;189: 106701.
Google Scholar
Chen C, et al. Using oncolytic virus to retask CD19-chimeric antigen receptor T cells for treatment of pancreatic cancer: toward a universal chimeric antigen receptor T-cell strategy for solid tumor. J Am Coll Surg. 2024;238(4):436–47.
Google Scholar
Ma R, et al. An oncolytic virus expressing IL15/IL15Rα combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma. Cancer Res. 2021;81(13):3635–48.
Google Scholar
Strecker MI, et al. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. Oncoimmunology. 2022;11(1):2127508.
Google Scholar
Wang Y, et al. Bacteriolytic therapy with Clostridium ghonii for experimental solid tumors. Biochem Biophys Res Commun. 2022;634:114–21.
Google Scholar
Goto Y, et al. Discovery of intratumoral oncolytic bacteria toward targeted anticancer theranostics. Adv Sci (Weinh). 2023;10(20): e2301679.
Google Scholar
Chintalapati S, et al. Tumor-isolated cutibacterium acnes as an effective tumor suppressive living drug. Biomed Pharmacother. 2024;170: 116041.
Google Scholar
Janku F, et al. Intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors. Clin Cancer Res. 2021;27(1):96–106.
Google Scholar
Tito RY, et al. Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development. Nat Med. 2024. https://doi.org/10.1038/s41591-024-02963-2.
Google Scholar
link
